

FIRM NEWS

Schulte Advises Caligan Partners in Settlement with AMAG Pharmaceuticals

October 31, 2019

Schulte advised Caligan Partners LP in its campaign at AMAG Pharmaceuticals Inc. (“AMAG”). The parties agreed to settle the consent solicitation launched by Caligan with AMAG agreeing to appoint two new members to their board, David Johnson, partner and co-founder of Caligan, and Paul Fonteyne, former chief executive officer of Boehringer Ingelheim USA.

The Schulte team was led by Ele Klein, partner and co-chair of the firm’s global Shareholder Activism Group. The team also included special counsel Adriana Schwartz, associates Brandon Gold, David Rothenberg, Abraham Schwartz and former Schulte lawyer William Tevlin.

Related People




**Ele
Klein**

Partner
New York




**Adriana
Schwartz**

Partner
New York



**Brandon
Gold**

Special Counsel
Washington, DC



**Abraham
Schwartz**

Associate
New York

Practices

SHAREHOLDER ACTIVISM